TOward Personalizing Care for Older Men With mCRPC - Understanding and Predicting Treatment Toxicities (the TOPCOP Study)
This study will examine the impact of modern treatments for metastatic Castrate Resistant
Prostate Cancer (mCRPC) on several relevant 'geriatric' domains such as daily function,
objective physical function, and falls. Additionally, the investigators study whether
frailty is associated with worse outcomes, and whether it is possible to predict the risk of
severe chemotherapy toxicity in older men.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society